Current trends of anticancer immunochemotherapy.

The paradigm of combinatorial anticancer therapy is nowadays deeply established into the clinical routine, reflecting the notion that – with a few notable exceptions – standalone chemo- or radiotherapeutic regimens are always insufficient to completely eradicate neoplastic lesions. Moreover, combining agents with distinct mechanisms of action potentially results in synergistic antineoplastic effects. This not only allows for the use of decreased drug dosages, de facto limiting the incidence and severity of side effects, but also significantly reduces the likelihood that malignant cells may become chemo- or radioresistant.